ClinicalTrials.gg
CompletedNCT00710268Updated Jan 14, 2015

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

A Phase 1 interventional study of AZD2281 and Bevacizumab in Neoplasm Metastasis, sponsored by AstraZeneca. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-14.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies testing olaparib in Neoplasm Metastasis — 5 open to participants now, 7 under way, none of them phase 3. olaparib · Neoplasm Metastasis.

Enrollment
9th of 13
18 · median 28
Started
2008
with 3 others
Phase 1
8 of 13
2 open now
Registered
3rd of 13
by date
Lead sponsor
4 of 13
AstraZeneca

Among the 13 studies testing olaparib in Neoplasm Metastasis, this one is the 9th largest by enrollment, is one of 4 that started in 2008, is one of 8 in phase 1, and was the 3rd registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

5 of the 13 studies testing olaparib in Neoplasm Metastasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing olaparib in Neoplasm Metastasis, or all of them as a file.
02

Study summary

Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.

03

Conditions studied

  • Neoplasm Metastasis

Browse trials for

Keywords

  • Bevacizumab
  • Poly(ADP ribose) polymerases
  • Metastatic Solid Tumours
  • PARP inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed cancer, not amenable to surgery or radiation therapy with curative intent
  • Adequate bone marrow, kidney and liver function in accordance with laboratory parameters set out in the protocol
  • Estimated of at least 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Disorders that may put the patient at risk of bleeding, including gastrointestinal perforation, intra-abdominal abcess, major surgery of the chest or abdomen, previous haemorrhage, coughing up blood or thrombotic event
  • Hypertension (high blood pressure) or significant cardiovascular disease
  • to Chinese hamster ovary cell products or other recombinant or humanised antibodies
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    1

    Dose Escalation Study 50, 100, 200, 400 mg

    Drug: AZD2281 · Drug: Bevacizumab

Interventions

  • Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing

    Also known as: Olaparib

  • IV administration10 mg/kg every 14 days

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. safety and tolerability of twice daily oral doses of AZD2281 when administered in combination with Bevacizumab to patients with advanced solid tumours by assessment of adverse events, vital signs, ECG, clinical chem, haematology, urinalysis and phys exam

    Time frame: various timepoints.

Secondary outcomes

  1. To compare exposure to AZD2281 when given alone and in combination with Bevacizumab, by assessment of appropriate derived PK parameters

    Time frame: various timepoints.

07

Study locations

2 sites
  • Research Site
    Manchester, United Kingdom
  • Research Site
    Oxford, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Mar 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2008
First posted
Jul 4, 2008
Start
Jun 2008
Primary completionActual
Mar 2009
CompletionActual
Nov 2009
Last update
Jan 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00710268
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 4, 2008
Start date
Jun 2008
Primary completion
Mar 2009
Completion
Nov 2009
Last update
Jan 14, 2015

Study contacts

James Carmichael, BSc MBChB MD FRCP
study director · KuDOS Pharmaceuticals Ltd
Malcolm Ranson
principal investigator · Christie Hospital, Manchester, UK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion